Print

Cytogen Corporation (CYTO) Reports Publication Validating the Utility of its Proprietary ProChart(TM) Database  
5/23/2007 12:44:09 PM

PRINCETON, N.J.--(BUSINESS WIRE)--Cytogen Corporation (NASDAQ: CYTO) today reported the publication of a review validating the utility of its ProChart™ database to help define the function of the WW domain-containing oxidoreductase (WWOX), an important tumor suppressor gene with known involvement in breast, prostate, lung, pancreatic, esophageal, and gastric cancers. The peer-reviewed article was published in the online edition (25 April 2007) of the Journal of Cellular Physiology as a Mini Review entitled “WWOX in biological control and tumorigenesis,” by Rami I. Aqeilan and Carlo M. Croce, epub 25 April 2007. The publication focuses on the most recent progress in understanding the function of WWOX as a tumor suppressor.
//-->